Experiment 623571
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Serenoa repens (ARECACEAE) |
| Citation | GRASSO,M: MONTESANO,A: BUONAGIDI,A: CASTELLI,M: LANIA,C: RIGATTI,P: ROCCO,F: CESANA,BM: BORGHI,C:. (1995). COMPARATIVE EFFECTS OF ALFUZOSIN VERSUS SERENOA REPENS IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA.. 48(1) |
| Amount utilized | |
| Compound isolated | |
| Disease | SIXTY-THREE PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA (BPH) ENTERED A DOUBLE-BLIND, COMPARATIVE, PARALLEL-GROUPS STUDY LASTING 3 WEEKS, CARRIED OUT TO COMPARE THE EFICACY AND SAFETY OF ALFUZOSIN 2.5 MG TID (N=32) VS SERENOA AREPENS 160 MG BID (N=31) IN BPH. EFFICACY WAS ASSESSED BOTH ON CLINICAL SYMPTOMS (BOYARSKY'S SCALE, VISUAL ANALOGUE SCALE, CLINICAL GLOBAL IMPARESSION), URINARY FLOW RATES (UROFLOWMETRY) AND RESIDUAL URINARY VOLUME (TRANSABDOMINAL ULTRASOUND). EVENTS AND REPORTED SIGNS WERE RECORDED THROUGHOUT THE ENTIRE STUDY. RESULTS: STATISTICALLY SIGNIFICANT AND CLINICALLY RELEVANT DIFFERENCES WERE FOUND BETWEEN THE TOW TREATMENTS IN FAVOUR OF ALFUZOSIN FOR BOYARSKY'S TOTAL SCORE DECREASE OF 38.8% FOR SERENOA REPENS) AND OBSTRUCTIVE SCORE, 37.8% FOR ALFUZOSIN; 23.1% FOR SERENOA REPENS; P = 0.01 FOR BOTH). |
| Dose amount | 320.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | HEXANE EXT |
| Gender | MALE |